The pharmaceutical sector is having a tremendous deal of change. Companies like Pfizer and Lilly are facing substantial product patent expirations. Plus, company pipelines are insufficient to exchange the revenues lost to patent expirations. Lastly, EU-based and US-based companies and US are shifting their organizations towards higher-growth markets in China, India, together with other Emerging Markets, creating internal organizational turmoil into their home markets.
- profile viewed 53 times